The most studied of all TAARs is TAAR1. In the human brain and model animals, it is present in areas responsible for the production of dopamine, serotonin, norepinephrine and glutamate - key neurotransmitters involved in the pathogenesis of diseases such as schizophrenia, depression, addictive behavior, and Parkinson's disease. Current scientific evidence suggests that selective TAAR1 agonists are capable of modulating the synthesis and transmission of dopamine, serotonin and glutamate, and therefore this receptor has become a target of modern antipsychotics undergoing clinical trials.
In addition to the central nervous system, TAAR1 is also present outside it, showing the most significant expression in the pancreas, stomach, intestines, blood leukocytes, thyroid gland, and placenta.
TAAR1 agonists have reached clinical trial level in the USA, Japan and Switzerland for the following clinical nosologies: schizophrenia, depression, anxiety and psychosis in Parkinson's disease. We are developing similar substances in Russia.